Search

everythinglearnresearchcommunity

for

Search:↓

Low-level light therapy significantly increased hair density and thickness in people with hair loss, but they didn't notice a difference.

Carboplatin-paclitaxel is preferred for advanced lung cancer due to its balance of affordability and patient well-being.

Arsenic trioxide effectively treats relapsed acute promyelocytic leukemia with manageable side effects.

SVF is safe and effective, but research quality is low; new guidelines are proposed to improve future studies.

Case-only trees and random forests improve predictions of treatment effects in clinical trials.

5-ARI therapy may help prevent prostate cancer progression.

Low-level light therapy safely improves hair coverage, thickness, and count in androgenetic alopecia patients.

The PROCLIPI study found markers that help predict outcomes in skin lymphoma patients.

Low-dose chemotherapy is safer, more effective, and cost-effective than surgery for treating bone lesions in children.

Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.

The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Different drug doses approved in Japan and the U.S. are not mainly due to different clinical responses, and ethnic factors should be considered in setting drug doses.

Safusidenib erbumine shows promise as a treatment for certain brain tumors, but mild side effects like hair loss need attention.

Androgen-deprivation therapies increase the risk of certain heart conditions, but testosterone treatment may help.

Auranofin shows promise as a cancer treatment, especially when combined with other therapies.

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

All four treatments for early rheumatoid arthritis had similar safety profiles.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

Baricitinib helps with early hair regrowth in people with alopecia areata.

A new method improves platelet testing for heart disease patients.

The nutritional supplement Pilopeptan® WOMAN improved hair growth and thickness in women with hair loss.

Mirvetuximab soravtansine improves quality of life and reduces symptoms more than standard chemotherapy in ovarian cancer patients.

CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.

The conclusion suggests that the zinc lozenge study is valid despite imperfect blinding, as many participants could not correctly identify their lozenge type.

Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.